Furosemide Increases Electrolyte Risks Without Improving BPD Outcomes

Furosemide showed no reduction in bronchopulmonary dysplasia (BPD) or death in preterm infants but significantly increased electrolyte abnormalities. In a 28-day trial involving 80 infants <29 weeks gestation, adverse event rates were similar between furosemide and placebo groups (~93%). No differences were observed in hearing loss or nephrocalcinosis. However, electrolyte-related adverse events were 4–8 times more likely with furosemide, warranting cautious use in this population.